{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Basal+Ganglia+Diseases&page=12",
    "query": {
      "condition": "Basal Ganglia Diseases",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 2092,
    "total_pages": 210,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Basal+Ganglia+Diseases&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Basal+Ganglia+Diseases&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T10:06:15.660Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01155349",
      "title": "Brain Fitness in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "InSight",
          "type": "BEHAVIORAL"
        },
        {
          "name": "No contact-control group",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2009-07",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2012-12-10",
      "last_synced_at": "2026-10-15T10:06:15.660Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01155349"
    },
    {
      "nct_id": "NCT01537549",
      "title": "Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Progressive Supranuclear Palsy"
      ],
      "interventions": [
        {
          "name": "alpha-lipoic acid and L-acetyl carnitine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 11,
      "start_date": "2010-09-14",
      "completion_date": "2015-04-07",
      "has_results": true,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-10-15T10:06:15.660Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01537549"
    },
    {
      "nct_id": "NCT02320266",
      "title": "Sensory Gating Measured With Microelectrode Recording (MER) During Deep Brain Stimulation (DBS) Surgery",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Parkinson's Disease",
        "Essential Tremor",
        "Dystonia",
        "Obsessive Compulsive Disorder"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 150,
      "start_date": "2014-12",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2024-05-13",
      "last_synced_at": "2026-10-15T10:06:15.660Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02320266"
    },
    {
      "nct_id": "NCT04384666",
      "title": "A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)",
          "type": "DRUG"
        },
        {
          "name": "Neupro 4 mg / 24 Hr. Transdermal Patch",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Luye Pharma Group Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 56,
      "start_date": "2020-06-02",
      "completion_date": "2020-08-10",
      "has_results": false,
      "last_update_posted_date": "2020-10-14",
      "last_synced_at": "2026-10-15T10:06:15.660Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04384666"
    },
    {
      "nct_id": "NCT04014387",
      "title": "Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Progressive Supranuclear Palsy(PSP)",
        "Insomnia"
      ],
      "interventions": [
        {
          "name": "Suvorexant",
          "type": "DRUG"
        },
        {
          "name": "Zolpidem",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2019-06-02",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-15T10:06:15.660Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04014387"
    },
    {
      "nct_id": "NCT07424365",
      "title": "Study to Investigate Vagus Nerve Stimulation to Augment Executive Function in Healthy and Cognitively Impaired Populations",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mild Cognitive Impairment (MCI)",
        "Parkinsons Disease (PD)",
        "Healthy Adult"
      ],
      "interventions": [
        {
          "name": "transcutaneous auricular vagus nerve stimulation",
          "type": "DEVICE"
        },
        {
          "name": "sham stimulation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 80,
      "start_date": "2025-05-19",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2026-02-20",
      "last_synced_at": "2026-10-15T10:06:15.660Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07424365"
    },
    {
      "nct_id": "NCT03732534",
      "title": "Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tourette Syndrome"
      ],
      "interventions": [
        {
          "name": "NBI-98854",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Years to 18 Years"
      },
      "enrollment_count": 6,
      "start_date": "2018-10-17",
      "completion_date": "2019-02-18",
      "has_results": true,
      "last_update_posted_date": "2022-04-19",
      "last_synced_at": "2026-10-15T10:06:15.660Z",
      "location_count": 9,
      "location_summary": "Anaheim, California • San Diego, California • Gulf Breeze, Florida + 6 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03732534"
    },
    {
      "nct_id": "NCT01451463",
      "title": "Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Huntington's Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2010-04",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2017-11-24",
      "last_synced_at": "2026-10-15T10:06:15.660Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01451463"
    },
    {
      "nct_id": "NCT00623363",
      "title": "Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "piclozotan",
          "type": "DRUG"
        },
        {
          "name": "0.9% sodium chloride (normal saline)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 27,
      "start_date": "2007-07-13",
      "completion_date": "2008-07-17",
      "has_results": true,
      "last_update_posted_date": "2021-03-11",
      "last_synced_at": "2026-10-15T10:06:15.660Z",
      "location_count": 5,
      "location_summary": "Fountain Valley, California • Tampa, Florida • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00623363"
    },
    {
      "nct_id": "NCT00239564",
      "title": "Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "IPX054 100 mg",
          "type": "DRUG"
        },
        {
          "name": "IPX054 150 mg",
          "type": "DRUG"
        },
        {
          "name": "IPX054 200 mg",
          "type": "DRUG"
        },
        {
          "name": "IPX054 250 mg",
          "type": "DRUG"
        },
        {
          "name": "IPX054 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Impax Laboratories, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2005-10",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2019-10-29",
      "last_synced_at": "2026-10-15T10:06:15.660Z",
      "location_count": 2,
      "location_summary": "Sunnyvale, California • Lawrence, Kansas",
      "locations": [
        {
          "city": "Sunnyvale",
          "state": "California"
        },
        {
          "city": "Lawrence",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00239564"
    }
  ]
}